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Possible mechanisms for this negative conversion was discussed. The
sample size was too little to associate with prognosis.
Conclusion: The receptor conversion mechanisms in metastatic lesions are
still unclear and debateful. It can be due to tumoral heterogeneity, genetic or
epigenetic alterations or intervening therapies. HER2 negative conversion
is mostly associated with chemotherapy and trastuzumab and is still con-
sidered as a bad prognostic factor. Awareness of this mechanisms is impor-
tant to decide the best therapy options especially in metastatic lesions.
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Background& objectives: There is evidence that calcifications in breast
cancer (BC) may have an active role in mitogenesis and upregulation of
gene expression.
Aim. To investigate the effect of presence of microcalcifications in breast
cancer tissue on Her2-neu expression.
Methods: In this study 468 tissue samples of BC were examined, 55 of
which hadmicrocalcifications, and 413 surgical biopsies showed no signs
of calcification. The immunohistochemical study of Her2-neu expression
and statistical analysis of the results (Chi-square test) was used in this
work. Samples with strong expression of the Her2-neu protein were se-
lected for the study.
Results: In the study of BC samples with calcifications, it was found that
the proportion of Her2-neu-positive cases among them was 20,93%. In
the control group of BC without calcification Her2-neu expression was
detected in 16,71% (p>0,05).
Conclusion: The expression of Her2-neu protein in the groups of BC
patients with the presence and absence of calcifications was not statisti-
cally different. Our study shows no association between the presence of
calcifications in breast cancer tissue and Her2-neu receptor expression.
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Background & objectives: Breast cancer is accompanied by metastatic
lymph nodes in 40% of cases. To identify molecular and genetic predic-
tive factors of metastases to regional lymph nodes in breast cancer pa-
tients based on the analysis of gene expression profile of the primary
tumour.
Methods: The study included 200 patients with morphologically verified
unicentric invasive breast cancer T1-4N0-3M0 in 2 groups: 100 cases
with metastases in lymph nodes and 100 cases without it. The molecular
genetic testing of tumour tissuewas carried out using reverse transcription
polymerase chain reaction (RT-PCR); the diagnostic panel consisted of
28 functional genes.
Results: The primary breast tumour in the group of patients with
metastases to regional lymph nodes was characterized by increased
proliferative activity based on expression of Ki-67 gene (p = 0.03),
as well as an increased level of mRNA of genes NAT (p = 0.04)
and CD68 (p <0.001) and decreased expression of PTEN (p
<0.001) and gene ESR1 (p = 0.04). According to the results of
discriminatory analysis, the predictive accuracy of presence or
absence of metastases to regional lymph nodes based on molecular
genetic testing of the primary tumour in 7 genes expression panel
was 91.9% and 78.8%, respectively.
Conclusion:Molecular genetic testing of the primary breast cancer tissue
using the panel of 7 genes (PTEN, CD68, CCNB1,MGB1,MYC, BCL2,
ESR1) can become an additional diagnostic tool for predicting the pres-
ence of lymph node metastases when planning the volume of axillary
surgery in breast cancer patients.
The reported study was supported by governmental grant № НИОКТР
АААА-А18-118053190016-7
E-PS-02-034
Changes of the luminal A subtype of breast cancer in local metastasis
K. Konyshev*, S. Sazonov, N. Kazantseva
*Institute of Medical Cell Technologies, Ural State Medical University,
Russia
Background & objectives: Subtype discordance in primary and meta-
static breast cancer (BC) is the possible reason of lower therapy effect.
Objective of the study: to evaluate changes in the luminal A subtype of
breast cancer in regional metastasis.
Methods: Samples of primary tumour and local metastasis obtained
from 36 patients were stained immunohistochemically with anti-
bodies to ER, PR, Her2/neu and Ki67. Primary tumour in all cases
had the luminal A subtype (according to St. Gallen 2015 consen-
sus). The frequency of changes in BC subtype in metastasis was
evaluated, the detected frequencies were compared using a Fischer
exact probability test.
Results: Regional metastasis had the discordant subtype in 11 cases
(30.6%, 95%, 16.9-48.3%) and concordant (luminal A) subtype in 25
of the 36 cases (69.4%, 95%, 51.7-83.1%). In 10 cases the metastatic
tumour had the luminal B subtype (27,8%, 95% DI 14,8-45,4%), in 1
case - triple negative subtype (2,8%, 95% DI 0.1-16.2%). The difference
in the frequency of primary tumour and metastasis subtype concordance
and discordance was statistically significant (p=0.002), as well as the
difference in the frequency of occurrence of luminal B and triple negative
subtypes of metastases (p=0.006).
Conclusion: Changes in the luminal A subtype of breast cancer in re-
gional metastasis were observed in 30.6% of cases, while the frequency of
cases with concordant subtype was significantly higher. Among cases
with discordance of primary tumour and regional metastases subtypes,
the luminal B subtype of the metastasis is more common (27.8%) than the
triple negative subtype (2.8%).
Supported by Ural State Medical University state assignment № 056-
00145-19-00
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Background & objectives: Secretory breast carcinoma (SBC) is a very
rare disease; it accounts for less than 0.05%. The SBC is defined by a
pattern of pathological, phenotypical and specific molecular features.
Reports of death from distant metastasis are very rare.
Methods: A 37 year-old woman with a stage IIB tumour. Diagnosed on
core-needle biopsy as a triple negative infiltrative carcinoma grade II of
SBR. She received a neoadjuvant chemotherapy with six cycles of a
combination of carboplatin AUC5 plus docetaxel for 3 cycles followed
by 3 cycles of FAC. She underwent a radical mastectomy with lymph
node dissection
Results: The patient had no response to chemotherapy, with an extensive
residual disease (RCBIII) of a SBC with no axillary lymph node metas-
tasis. The tumour cells showed a mild positivity for oestrogen receptor
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